Design and Evaluation of Hypoxia Enhanced Bombesin Analogs for Prostate Cancer

缺氧增强铃蟾肽类似物治疗前列腺癌的设计和评价

• 批准号: 8013460
• 负责人: Jered C Garrison
• 金额: $ 24.9万
• 依托单位: UNIVERSITY OF NEBRASKA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8013460
• 关键词: 90Y; Affinity; Binding; Bombesin; Cancer Etiology; Cancer Model; Cessation of life; Detection; Diagnostic; Drug Kinetics; Evaluation; Hypoxia; ICAM1 gene; Imaging Techniques; In Vitro; Label; Malignant Neoplasms; Malignant neoplasm of prostate; Peptides; Pharmaceutical Preparations; Pilot Projects; Property; Prostate; Radiopharmaceuticals; Staging; Technology; Therapeutic; United States; X-Ray Computed Tomography; analog; design; in vivo; men; molecular imaging; mouse model; receptor; single photon emission computed tomography; tool; tumor; vector

DESCRIPTION (provided by applicant): Career Goals: My immediate goals are to obtain the required training to become a translational research capable of developing diagnostic/therapeutic cancer agents for clinical trials. My long-term goals are to becoming an independent research scientist at an academic medical center specializing in cancer research. Research Project: Our proposal is to enhance the efficacy of diagnostic radiopharmaceuticals for the detection of prostate cancer by incorporating hypoxia trapping agents into the structure of tumor specific targeted peptides. We propose to test our theory by incorporating nitroimidazoles (hypoxia trapping agents) into the structure of the Bombesin (BBN) peptide. The proposed 1111n-BBN analogs are expected to exhibit increased residence time of the diagnostic agent in prostate tumors. The increase in retention time in the hypoxic sections of the tumor will provide significantly enhanced diagnostic images by yielding higher tumor to non-target ratios. If successful, this technology could drastically enhance the efficacy of BBN and other tumor specific targeted small molecules, peptides and antibodies. Career Development: The mentorship team in this application is designed to educate the applicant in the necessary skill set to become a translational cancer researcher. The basic and preclinical laboratory training will be provided by the mentor (Hoffman) and co-mentor (Volkert). The co-mentor (Perry) will provide the applicant with a clinical perspective on radiopharmaceutical development and how it relates to patient care. The formal training program will include a combination of didactic lectures, attendance at seminar presentations, practical training in the use of mouse models and oncology, practical training in the use of molecular and anatomic imaging techniques. Environment: The applicant will have access to Dr. Hoffman's laboratory (2,600 sq.ft.) fully equipped for the proposed synthesis and evaluation of the hypoxia enhanced Bombesin analogs. Also, the applicant will have access to the VA Animal Research Facility, Biomolecular Imaging Center, VA Nuclear Medicine Service, MU Cell and Immunobiology Core Facility and the MU Structural Biology Core.

描述（由申请人提供）： 职业目标：我的近期目标是获得所需的培训，成为一名能够开发用于临床试验的诊断/治疗性癌症药物的转化研究人员。我的长期目标是成为一名专门从事癌症研究的学术医疗中心的独立研究科学家。 研究项目：我们的建议是通过将缺氧捕获剂纳入肿瘤特异性靶向肽的结构中，提高诊断放射性药物检测前列腺癌的功效。我们建议通过将硝基咪唑（缺氧捕获剂）合并到铃蟾肽（BBN）肽的结构中来测试我们的理论。预计所提出的 1111n-BBN 类似物会延长诊断剂在前列腺肿瘤中的停留时间。肿瘤缺氧部分保留时间的增加将通过产生更高的肿瘤与非目标比率来提供显着增强的诊断图像。如果成功，这项技术可以大大增强 BBN 和其他肿瘤特异性靶向小分子、肽和抗体的功效。 职业发展：本申请中的导师团队旨在教育申请人成为转化癌症研究员所需的技能。基础和临床前实验室培训将由导师（Hoffman）和共同导师（Volkert）提供。共同导师（佩里）将为申请人提供有关放射性药物开发及其与患者护理的关系的临床观点。正式培训计划将包括教学讲座、参加研讨会演示、使用小鼠模型和肿瘤学的实践培训、使用分子和解剖成像技术的实践培训。 环境：申请人将可以使用霍夫曼博士的实验室（2,600 平方英尺），该实验室设备齐全，用于缺氧增强铃贝星类似物的拟议合成和评估。此外，申请人还可以使用 VA 动物研究设施、生物分子成像中心、VA 核医学服务、MU 细胞和免疫生物学核心设施以及 MU 结构生物学核心。